

Press Release

Regeneus to present at 3rd Annual Regenerative Medicine Investor Day March 25 in New York

Sydney, Australia – 23 March 2015

Regeneus Ltd (ASX: RGS) announced today that John Martin, CEO, will present at the 3rd Annual Regenerative Medicine Investor Day to be held Wednesday, March 25, 2015 in New York City.

Organised by the Alliance for Regenerative Medicine (ARM) and co-hosted with Piper Jaffray, a leading full-service investment bank and asset management firm serving clients in the U.S. and internationally this one-day investor meeting provides institutional, strategic and venture investors with unique insight into the financing opportunities for advanced therapies-based treatment and tools. The program includes clinical and commercial experts who are on-hand to address specific questions regarding the outlook for these products, as well as offer insight into how advanced therapies could impact the standard of care in key therapeutic areas. In addition to presentations by more than 30 leading companies from across the globe, the event includes dynamic, interactive panels featuring research analysts covering the space, key clinical opinion leaders and top company CEOs. These discussions will explore themes specific to cell and gene therapy such as commercialisation, market access and pricing for breakthrough technologies, gene therapy delivery and upcoming milestones in the adoptive T-cell therapy space.

The following are specific details regarding Regeneus' presentation:

Event: **ARM's Regen Med Investor Day**

Date: March 25, 2015

Time: 4.50 – 5.05pm (EDT)

Location: Metropolitan Club, One East 60th Street, New York, NY 10022

A live-streaming webcast of all panels and company presentations will be available at: <http://www.arminvestorday.com/webcast> and will be published on the event's website shortly after the conference.

Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at lparsons@alliancerm.org. Please visit <http://www.arminvestorday.com> for more information.

About Regeneus:

Regeneus Ltd (ASX: RGS) is a clinical-stage regenerative medicine company developing a patented portfolio of cell therapies to address significant unmet medical needs in the human and veterinary health markets with a focus on musculoskeletal disease, oncology and dermatology.

The company has four therapies targeting human conditions in various stages of development including two products approaching first-in-human Phase I: Progenza is an allogeneic off-the-shelf adipose stem cell therapy to treat musculoskeletal conditions and RGS4K is a human autologous personalized therapeutic cancer vaccine to treat a wide range of cancer types. The company has developed a stem cell based cream targeting inflammatory skin conditions and HiQCell is a commercial autologous therapy for the treatment of musculoskeletal conditions. The company has two therapies targeting animal conditions: CryoShot is a clinical-phase allogeneic off-the-shelf adipose stem cell therapy for the treatment of canine and equine musculoskeletal conditions and Kvax is a commercial autologous personalized therapeutic cancer vaccine in marketing trials.

About the Alliance for Regenerative Medicine

The Alliance for Regenerative Medicine (ARM) is an international multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine worldwide. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, D.C. to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today, ARM has more than 200 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit <http://www.alliancerm.org>.

ENDS

Contact for further information:**Investors:**

Sandra McIntosh
Company Secretary
Regeneus Ltd
T: +61 2 9499 8010
E: investors@regeneus.com.au or go to www.regeneus.com.au